Announcements Trials
Browse Landscape

Phase

Phase 3 7

Status

Recruiting 6Active not recruiting 1

Sponsor Class

OTHER 62INDUSTRY 52NIH 19NETWORK 7

Study Type

Interventional 7

Sponsor

Cancer Type

Plasma cell 7

Conditions

Multiple Myeloma 6Smoldering Multiple Myeloma 1

Interventions

Specimen Handling 46Magnetic Resonance Spectroscopy 37Cyclophosphamide 28Vincristine 20Radiation 19Dexamethasone 19Cisplatin 18Biopsy 18Radiotherapy 17Etoposide 17Carboplatin 16Cytarabine 13Leucovorin 12daratumumab 11Methotrexate 11durvalumab 10Standard of Care 10Radiotherapy, Intensity-Modulated 10Platinum 10Gemcitabine 10Doxorubicin 10Docetaxel 10Practice Guidelines as Topic 9Calcium Dobesilate 91,2-diaminocyclohexaneplatinum II citrate 9merphos 8dexamethasone acetate 8dexamethasone 21-phosphate 8auricularum 8X-Rays 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
NETWORK × Lenalidomide × 90 days × Clear all
NCT03937635 2026-05-15

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

Eastern Cooperative Oncology Group

Phase 3 Recruiting
288 enrolled
Plasma cell

Smoldering Multiple Myeloma

NCT04566328 2026-05-15

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

Eastern Cooperative Oncology Group

Phase 3 Recruiting
1,450 enrolled
Plasma cell

Multiple Myeloma

NCT06182774 2026-05-12

Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma

Canadian Cancer Trials Group

Phase 3 Recruiting
570 enrolled
Plasma cell

Multiple Myeloma

NCT06918002 2026-04-02

ElLen

Intergroupe Francophone du Myelome

Phase 3 Recruiting
824 enrolled
Plasma cell

Multiple Myeloma

NCT05243797 2026-03-25

MajesTEC-4

European Myeloma Network B.V.

Phase 3 Recruiting
1,594 enrolled
Plasma cell

Multiple Myeloma

NCT06932562 2026-03-25

A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant

European Myeloma Network B.V.

Phase 3 Recruiting
1,000 enrolled
Plasma cell

Multiple Myeloma

NCT05257083 2026-03-17

CARTITUDE-6

European Myeloma Network B.V.

Phase 3 Active not recruiting
759 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡